Public Summary

Summary for ARTG Entry:	303710 Chondroplex
ARTG entry for	Medicine Listed
Sponsor	FIT-BioCeuticals Limited
Postal Address	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia
ARTG Start Date	30/05/2018
Product Category	Medicine
Status	Active
Approval Area	Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Chondroplex

Product Type Single Medicine Product **Effective Date** 5/10/2018

Permitted Indications

Anti-inflammatory/relieve inflammation

Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis

Helps enhance/promote healthy joint function

Maintain/support joint health

Decrease/reduce/relieve mild joint inflammation/swelling

Maintain/support joint mobility/flexibility

Decrease/reduce/relieve mild joint pain/soreness

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must only refer to mild joint symptoms.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

bovine sodium chondroitin sulfate	**293.83 mg**
Equivalent: chondroitin sulfate	267 mg
dimethyl sulfone	**399.9999 mg**
glucosamine sulfate sodium chloride	**628.14 mg**
Equivalent: glucosamine sulfate	500 mg

Other Ingredients (Excipients)

Carnauba Wax
colloidal anhydrous silica
croscarmellose sodium
crospovidone
hyprolose
indigo carmine
lecithin
macrogol 3000
magnesium stearate
microcrystalline cellulose
polyvinyl alcohol
povidone
purified talc
silicon dioxide
titanium dioxide

Public Summary